Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MRI Interventions Inc (OTC: MRIC).

Full DD Report for MRIC

You must become a subscriber to view this report.


Recent News from (OTC: MRIC)

MRI Interventions' (MRIC) CEO Joe Burnett on Q2 2018 Results - Earnings Call Transcript
MRI Interventions, Inc. (MRIC) Q2 2018 Earnings Conference Call August 14, 2018 4:30 PM ET Executives Joe Burnett – Chief Executive Officer Hal Hurwitz – Chief Financial Officer Analysts Scott Billeadeau – Walrus Partners Kris Tuttle – SoundView ...
Source: SeekingAlpha
Date: August, 14 2018 20:28
MRI Interventions Reports Second Quarter Results
IRVINE, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC) (the “Company”) today announced financial results for its second fiscal quarter ended June 30, 2018. Second Quarter 2018 Highlights Total revenue for the second quarter was $1.65 ...
Source: GlobeNewswire
Date: August, 14 2018 16:05
MRI Interventions, Inc. to Announce Second Quarter 2018 Results on August 14
IRVINE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) announced that it will release financial results for its 2018 second quarter, which ended June 30, 2018, on Tuesday, August 14, 2018 after the market close. The company will subsequently conduct a confere...
Source: GlobeNewswire
Date: August, 07 2018 16:05
MRI Interventions, Inc. to Webcast at LD Micro Conference
IRVINE, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) announced that it will webcast its presentation at the 8th annual LD Micro Invitational Conference on Tuesday, June 5. Joe Burnett, Chief Executive Officer, is scheduled to present at 11:00 am Pacific Tim...
Source: GlobeNewswire
Date: June, 04 2018 08:00
MRI Interventions' ClearPoint® Neuro Navigation System to Be Featured at ASSFN Biennial Meeting
IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on Magnetic Resonance Imaging (MRI)-Guided Neurosurgical procedures, today announced that its ClearPoint ® Neuro Navigation System will be featured ...
Source: GlobeNewswire
Date: May, 29 2018 09:00
MRI Interventions to Present at the LD Micro Invitational Conference on June 5
LOS ANGELES, CA / ACCESSWIRE / May 22, 2018 / MRI Interventions, Inc. (OTCQB: MRIC), today announced that Chief Executive Officer Joe Burnett will present at the 8th annual LD Micro Invitational on Tuesday, June 5 at 11:00 AM PST. The event will be held at the Luxe Sunset Hotel in Bel Air,...
Source: ACCESSWIRE
Date: May, 22 2018 08:00
MRI Interventions Announces CE Mark for the SmartFlow® Cannula
IRVINE, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) a leader in Precision MRI-Guided Therapy, including Biologics and Drug Delivery, today announced CE Mark approval for the SmartFlow Cannula. The CE Marked SmartFlow device is indicated for the delivery of ...
Source: GlobeNewswire
Date: May, 17 2018 16:05
MRI Interventions' (MRIC) CEO Joseph Burnett on Q1 2018 Results - Earnings Call Transcript
MRI Interventions Inc (MRIC) Q1 2018 Earnings Conference Call May 15, 2018 16:30 P.M. ET Executives Joseph M. Burnett - CEO Harold A. Hurwitz - CFO and Secretary Analysts Kris Tuttle - SoundView Technology Group Larry Haimovitch - HMTC Presentation Operator Greeti...
Source: SeekingAlpha
Date: May, 15 2018 17:56
MRI Interventions Announces Strategic Agreement with Voyager Therapeutics for Neurosurgical Device Service, Supply and Development
IRVINE, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced a strategic agreement with Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. T...
Source: GlobeNewswire
Date: May, 15 2018 16:06
MRI Interventions Reports First Quarter Results, New Strategic Initiatives to Further Growth
IRVINE, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) (the “Company”) today announced financial results for its first fiscal quarter ended March 31, 2018. First Quarter 2018 Highlights Total revenue decreased 19% to $1.6 million for th...
Source: GlobeNewswire
Date: May, 15 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-101.801.861.861.74802
2018-12-071.821.8951.8951.822,428
2018-12-061.851.851.851.851,000
2018-12-051.971.8921.971.742,305
2018-12-041.971.8921.971.742,305

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-071002,4284.1186Cover
2018-12-041,6412,30571.1931Short
2018-12-0325979732.4969Cover
2018-11-302187,2782.9953Cover
2018-11-2910037526.6667Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MRIC.


About MRI Interventions Inc (OTC: MRIC)

Logo for MRI Interventions Inc (OTC: MRIC)

MRI Interventions, a commercial stage medical technology company, is focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures. The company s FDA cleared and CE marked ClearPoint system utilizes a hospital s existing diagnostic or intraoperative MRI scanner to enable a range of minimally invasive procedures in the brain. Building on the imaging power of MRI, the company s interventional platforms strive to improve patient care while reducing procedure costs and times. For more information, please visit www.MRIInterventions.com.

 

Contact Information

 

 

Current Management

  • Joseph M. Burnett / CEO, President
  • Peter G. Piferi / COO
    • Mr. Piferi joined the company in December as Chief Operating Officer. He has over years of experience in the areas of product development, operations, engineering and production in the medical device industry. From March to December , Mr. Piferi served as Vice President, Endovascular Technologies for Edwards Lifesciences Corporation. In addition, he has served as Vice President at Kriton Medical Inc. and Orbus Medical Technologies, Inc., and as Director of Advanced Engineering at Cordis Corporation.
  • Harold Hurwitz / CFO
    • Mr. Hurwitz joined the company in March . From February to January , Mr. Hurwitz served as Chief Executive Officer of ProDex, Inc., a publiclytraded contract engineering and manufacturing company serving the medical device, factory automation and scientific research markets. Mr. Hurwitz also was Chief Financial Officer of ProDex from October , when he joined that company, to January , and was a Director from May to January . From April to February , Mr. Hurwitz served as Chief Financial Officer and Vice President of Interventional Spine, Inc., a venturebacked medical device company. Prior to joining Interventional Spine, Mr. Hurwitz served as Principal Consultant with McDermott amp Bull, a retained executive search firm, from December to March , where he led the life science and medical technology practice. Mr. Hurwitz served as an independent consultant from December to December , with his primary client during that time being Micro Therapeutics, Inc., then a publiclytraded medical device company subsequently acquired by ev , Inc., and now part of Medtronic plc . He was Chief Financial Officer of Micro Therapeutics, Inc. from December to December . Earlier in his career, Mr. Hurwitz was a Partner with Coopers amp Lybrand L.L.P. now part of PricewaterhouseCoopers LLP , where he was a Business Assurance Partner.
  • Wendelin Maners / VP, Sales amp Mktg.
    • Ms. Maners joined the company in December as Vice President, Marketing, and in April became Vice President, Sales and Marketing. She has more than two decades of global medical device experience focused on the marketing, acquisition, and licensing of medical device technologies. Prior to joining MRI Interventions, Ms. Maners served as Vice President, Emerging Technologies with CSA Medical, where she managed commercial marketing for the company s products, led market development efforts for the company s emerging applications in new market and disease segments and developed internal and external product training programs. Prior to her time with CSA Medical, Ms. Maners served for over years in various roles at Boston Scientific Corporation, most recently as Vice President, Strategy and Business Development. During that time, she developed and executed acquisition strategies in the Neuromodulation and Electrophysiology markets, managed and built technology and venture capital business relationships to assemble a portfolio of investment options for supported divisions and served as a delegate Board member/observer for Boston Scientific investments, including Cyberonics, Northstar Neuroscience, Neuropace, Intelect Medical, IntraPace, Quallion and MRI Interventions.
  • Kimble L. Jenkins / Chairman
  • Joseph M. Burnett /
  • R. John Fletcher / Independent Director, Audit Committee Member, Nominating Committee Member
  • John N. Spencer, Jr. / Independent Director, Audit Committee Member, Compensation Committee Member

Current Share Structure

  • Market Cap: $34,766,211 - 03/09/2018
  • Authorized: 200,000,000 - 03/09/2018
  • Issue and Outstanding: 10,730,312 - 03/09/2018
  • Float: 1,501,436 - 02/22/2017

 


Recent Filings from (OTC: MRIC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 17 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 21 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: March, 21 2018

 

 


Daily Technical Chart for (OTC: MRIC)

Daily Technical Chart for (OTC: MRIC)


Stay tuned for daily updates and more on (OTC: MRIC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MRIC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MRIC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MRIC and does not buy, sell, or trade any shares of MRIC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/